MedTrace Logo

Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops

NCT04782271 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-03-31

No results posted yet for this study

Summary

Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.

Conditions

  • Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers
  • Choroidal Neovascularization

Interventions

DRUG

SYL18001 sodium Low dose q.d

1 drop in the randomized eye once daily

DRUG

SYL18001 sodium Middle dose q.d

1 drop in the randomized eye once daily

DRUG

SYL18001 sodium High dose q.d

1 drop in the randomized eye once daily

DRUG

SYL18001 sodium High dose b.i.d

1 drop in the randomized eye twice daily

Sponsors & Collaborators

  • Sylentis, S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2021-12-21
Completion
2021-12-21

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04782271 on ClinicalTrials.gov